$7.6-billion Elanco deal gets FTC green lightJuly 15, 2020Elanco Animal Health has received unanimous approval for its $7.6-billion acquisition of Bayer’s animal health division.
Education Center - SponsoredWhat veterinarians need to know about real estate sale-leasebacksby • Vet Asset AdvisorsOftentimes, veterinarians own not only their practice, but also their real estate. And equally as often, the owners do not realize how valuable their real estate has become.
Bayer, Pharamaron union to streamline drug developmentNovember 29, 2019A partnership between Bayer and life sciences R&D company, Pharamaron, aims to accelerate the production of innovative therapies to address the unmet medical needs of animal patients.
Bayer pledges $200k in domestic violence aidOctober 8, 2019A Bayer-sponsored grant program that aims to support victims of domestic violence by ensuring the safety of their pets has received an extra boost.
Elanco acquires Bayer’s animal health division in $7.6-billion dealAugust 20, 2019Following months of speculation, two major industry players have finalized a deal, resulting in the creation of the second-largest animal health company in the world.
Bayer and Elanco rumored to be mergingJuly 10, 2019A significant animal health merger might be in the works between pharmaceutical company Bayer and Elanco Animal Health.
Bayer Animal Health, Nutreco to enhance nutritional health of farm animalsMay 21, 2019Bayer Animal Health and Nutreco are combining their efforts to improve the nutritional and health performance of farm animals. The companies have signed a global research and development collaboration agreement. Their first project together will be to come up with innovative solutions for gastrointestinal health in dairy and beef cattle. “The agreement further demonstrates our strong commitment to drive innovation in the farm animal space,” says Douglas Hutchens, DVM, PhD, Bayer’s head of drug …
Bayer, adivo to develop therapeutic antibodiesApril 17, 2019Bayer Animal Health and adivo have signed an agreement to develop therapeutic antibodies for companion animals. The collaboration may be good news for veterinary medicine. Although the use of therapeutic antibodies is not widespread, they offer a variety of healing options for diseases that still cannot be treated with current technology. “Today’s agreement is another example of how we realize our innovation strategy,” says Douglas Hutchens, DVM, PhD, Bayer Animal Health’s head of drug …
Bayer to leave animal health marketDecember 7, 2018A longtime player in animal health care is leaving the industry. In 2019, Bayer Animal Health will make pharmaceuticals, consumer health, and crop science primary focus areas.
